Organogenesis Holdings Inc. ORGO
0.81 USD -0.15 (-16.05%)
Regular-session close
0.84 +0.03 +3.12%
After hours · Nov 13, 5:53 PM ET
0.81 Day range 0.9614
0.756 52-week range 6.21
- YTD
- -84.36%
- 1 year
- -86.95%
News
seekingalpha.com Organogenesis Holdings Inc. (ORGO) Q3 2026 Earnings Call Transcript Organogenesis Holdings Inc. ( ORGO ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Gary Gillheeney - President, CEO, Chair of the Board David Francisco - Chief Financial…
fool.com Organogenesis: 3 Key Takeaways for Long-Term Investors Organogenesis increased third quarter net product revenue 6% quarter over quarter. Management expects annual operating expense reductions of approximately $45 million.
marketbeat.com Organogenesis Q3 Earnings Call Highlights Organogenesis NASDAQ: ORGO reported a 70% year-over-year decline in third-quarter net product revenue and lowered the upper end of its full-year revenue outlook as the skin substitute market…
benzinga.com Organogenesis Holdings Q3 2026 Earnings Call Transcript Organogenesis Holdings (NASDAQ:ORGO) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Organogenesis Hldgs Q3 Adj. EPS $(0.25) Misses $(0.17) Estimate, Sales $45.457M Miss $52.100M Estimate Organogenesis Hldgs (NASDAQ:ORGO) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.17) by 47.06 percent. This is a 238.89 percent decrease over…
benzinga.com Organogenesis Holdings Narrows FY2026 Sales Guidance from $179.000M-$215.000M to $179.400M-$200.000M vs $196.050M Est Organogenesis Holdings (NASDAQ:ORGO) narrows FY2026 sales outlook from $179.000 million-$215.000 million to $179.400 million-$200.000 million vs $196.050 million estimate.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers TransMedics Group (NASDAQ:TMDX) stock rose 17.6% to $81.16 during Thursday's after-market session. The company's market cap stands at $2.5 billion. The company's, Q3 earnings came out today.
globenewswire.com Organogenesis Holdings Inc. Reports Third Quarter 2026 Financial Results CANTON, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the…
benzinga.com Organogenesis Holdings Announces Publication Of Results From PREPARE, Multicenter, RCT Evaluating PuraPlyAM Plus SoC Compared To SoC Alone In Hard-To-Heal Diabetic Foot Ulcers Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced…
globenewswire.com Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers CANTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and…
globenewswire.com Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026 CANTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the…
marketwatch.com These beaten-down stocks could bounce back in January, if history is any guide Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
defenseworld.net BlackRock Inc. Purchases Shares of 7,249,528 Organogenesis $ORGO BlackRock Inc. acquired a new position in Organogenesis (NASDAQ: ORGO) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers AVITA Medical (NASDAQ:RCEL) stock rose 58.4% to $7.53 during Friday's regular session. The company's market cap stands at $146.1 million. As per the press release, Q2 earnings came out…
benzinga.com Truist Securities Maintains Hold on Organogenesis Holdings, Lowers Price Target to $2 Truist Securities analyst Ravi Misra maintains Organogenesis Holdings (NASDAQ:ORGO) with a Hold and lowers the price target from $3 to $2.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Doximity (NYSE:DOCS) stock rose 85.1% to $38.25 during Friday's pre-market session. The market value of their outstanding shares is at $3.7 billion. As per the news, the Q1 earnings report…
benzinga.com Trade Desk Posts Downbeat Q2 Results, Joins Sezzle, Resmed, Ouster And Other Big Stocks Moving Lower In Friday’s Pre-Market Session US stock futures mixed, Nasdaq 100 futures up 100 points. Trade Desk Inc shares down 27.7% after weak Q2 results. Other stocks also lower premarket.
benzinga.com Why Atlassian Shares Are Trading Higher By More Than 30%; Here Are 20 Stocks Moving Premarket Atlassian Corp (NASDAQ: TEAM) reported strong Q4 results, beating revenue and earnings estimates. Stock jumped 30.7% in pre-market trading.
marketbeat.com Organogenesis Q2 Earnings Call Highlights Organogenesis NASDAQ: ORGO reported a sharp year-over-year decline in second-quarter revenue as the skin substitute market continued to adjust to coverage and payment changes from the Centers for…
seekingalpha.com Organogenesis Holdings Inc. (ORGO) Q2 2026 Earnings Call Transcript Organogenesis Holdings Inc. (ORGO) Q2 2026 Earnings Call Transcript
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Doximity (NYSE:DOCS) stock increased by 65.6% to $34.22 during Thursday's after-market session. The market value of their outstanding shares is at $3.8 billion. The company's, Q1 earnings…
benzinga.com Organogenesis Holdings Lowers FY2026 Sales Guidance from $270.000M-$310.000M to $179.000M-$215.000M vs $282.850M Est Organogenesis Holdings (NASDAQ:ORGO) lowers FY2026 sales outlook from $270.000 million-$310.000 million to $179.000 million-$215.000 million vs $282.850 million estimate.
globenewswire.com Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results CANTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the…
globenewswire.com Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers CANTON, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and…
benzinga.com Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session Pegasystems Inc (NASDAQ: PEGA) reported lower-than-expected earnings and sales, causing stocks to fall 16% in pre-market trading.
benzinga.com Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session US stock futures up, Nasdaq 100 gains 1%. Danaher Corp (DHR) shares fall 10.1% in pre-market trading. Other stocks also decline.
benzinga.com Ryanair Posts Weak Q1 Results, Joins HDFC Bank And Other Big Stocks Moving Lower In Monday’s Pre-Market Session US stock futures higher with Nasdaq 100 up 150 points. Ryanair (RYAAY) shares fall after weak Q1 results. Other stocks declining in pre-market.
globenewswire.com Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026 CANTON, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the…- benzinga.com Organogenesis' Biologics License Application For ReNu Receives FDA's Acceptance For Review To Treat Pain In Symptomatic Knee Osteoarthritis Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced…
globenewswire.com Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis CANTON, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and…
seekingalpha.com Organogenesis: Mesmerized By Wound Care Struggles, Upcoming ReNu Blockbuster Overlooked Organogenesis is grappling with significant revenue declines in 2026 due to adverse Medicare policy changes impacting its core skin substitute products. 2025 marked a peak year for ORGO, but 2026…
benzinga.com This Suncrete Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday Top analysts change outlook on top names. Check out analyst ratings page for all changes. RMIX, ABSI, and ORGO get coverage with targets.- benzinga.com Truist Securities Initiates Coverage On Organogenesis Holdings with Hold Rating, Announces Price Target of $3 Truist Securities analyst Ravi Misra initiates coverage on Organogenesis Holdings (NASDAQ:ORGO) with a Hold rating and announces Price Target of $3.
benzinga.com Why Estee Lauder Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket Estee Lauder (EL) shares jumped 11.8% in pre-market trading after ending discussions with Puig. Other gainers include PCLA, AKTX, LFS, BIYA, QTEX, GOVX, COHN, SQNS, and IMAX.
benzinga.com Deckers Outdoor, UP Fintech And Other Big Stocks Moving Lower In Friday's Pre-Market Session U.S. stock futures rise with Dow gaining 300 points. Deckers Outdoor Corp shares fall after beating Q4 revenue estimates and providing fiscal 2027 guidance.
marketbeat.com Organogenesis Q1 Earnings Call Highlights Organogenesis NASDAQ: ORGO reported a sharp year-over-year revenue decline in the first quarter of 2026, with executives pointing to significant disruption in the skin substitute market following…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Forward Air Posts Downbeat Q1 Results, Joins Upwork, HubSpot And Other Big Stocks Moving Lower In Friday's Pre-Market Session U.S. stock futures up, Dow futures gain approx. 100 pts. Forward Air Corp (FWRD) shares down 42.8% in pre-market trading. Other stocks also down.
benzinga.com Forward Air Posts Downbeat Q1 Results, Joins Upwork, HubSpot And Other Big Stocks Moving Lower In Friday's Pre-Market Session U.S. stock futures up, Dow futures gain approx. 100 pts. Forward Air Corp (FWRD) shares down 42.8% in pre-market trading. Other stocks also down.
seekingalpha.com Organogenesis Holdings Inc. (ORGO) Q1 2026 Earnings Call Transcript Organogenesis Holdings Inc. (ORGO) Q1 2026 Earnings Call Transcript- benzinga.com Organogenesis Holdings Lowers FY2026 Sales Guidance from $350.000M-$420.000M to $270.000M-$310.000M vs $401.200M Est Organogenesis Holdings (NASDAQ:ORGO) lowers FY2026 sales outlook from $350.000 million-$420.000 million to $270.000 million-$310.000 million vs $401.200 million estimate.
benzinga.com Organogenesis Hldgs Q1 Adj. EPS $(0.34) Misses $(0.31) Estimate, Sales $36.250M Miss $43.300M Estimate Organogenesis Hldgs (NASDAQ:ORGO) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.31) by 9.68 percent. This is a 209.09 percent decrease over losses…
globenewswire.com Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results CANTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the…
globenewswire.com Organogenesis Completes Rolling Submission of Biologics License Application for ReNu® If approved, ReNu® will revolutionize treatment options for millions of patients with knee OA pain If approved, ReNu® will revolutionize treatment options for millions of patients with knee OA pain
benzinga.com What's Going On With Organogenesis Stock On Wednesday? Wound closure at 12 weeks was a key highlight, indicating the product's efficacy.
benzinga.com What's Going On With Organogenesis Stock On Wednesday? Organogenesis stock rises after PuraPly AM trial shows improved diabetic foot ulcer closure; RSI signals oversold levels amid weak trend.
benzinga.com Organogenesis Stock Rockets After Diabetic Foot Ulcer Trial Posts Statistically Significant Win Organogenesis stock jumps after PuraPly AM trial meets endpoint, while ReNu shows mixed Phase 3 data and advances toward FDA filing.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Silo Pharma Shares Are Trading Higher By Around 52%; Here Are 20 Stocks Moving Premarket SILO stock rose 51.8% in pre-market trading after its PTSD treatment pipeline received a patent from the European Patent Office targeting 5-HT4.
benzinga.com Reported Earlier, Organogenesis Reports PuraPly AM Meets Primary Endpoint In Randomized Controlled Trial, Demonstrating Statistically Significant DFU Wound Closure At 12 Weeks Statistically significant (p<0.0477) DFU wound closure at 12 weeksRCT compared PuraPly®AM plus standard of care to standard of care aloneResults strengthen existing clinical evidence supporting…